Dr. Jason Alfred Castellanos, MD

Dr. Castellanos practices at Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University.

Dr. Castellanos' NPI, 1124262811, was assigned on April 24, 2009. Dr. Castellanos graduated from Vanderbilt University School Of Medicine in 2009. Dr. Castellanos holds Pennsylvania license MD471916.

Dr. Castellanos' primary practice is Fox Chase Cancer Center, at 333 Cottman Avenue, Philadelphia, PA 19111.

Dr. Castellanos' primary practice is Fox Chase Cancer Center in Philadelphia, Pennsylvania, part of Thomas Jefferson University. Dr. Castellanos is also affiliated with Temple University Hospital. The medical group on file is Temple Faculty Physicians. Dmand AI also links Dr. Castellanos to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Castellanos practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Castellanos' primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Castellanos is board certified in clinical informatics by the American Board of Emergency Medicine. Dmand AI has Dr. Castellanos' licenses on file in 3 states: Pennsylvania, New York and Tennessee.

Dmand AI lists acute gallbladder or bile duct inflammation, appendectomy, esophagus, stomach, or upper small intestine surgery and gallbladder removal among the conditions Dr. Castellanos treats.

CMS data shows 218 Medicare services from Dr. Castellanos across 6 procedure codes in 2024, for 118 Medicare patients. Medicare paid $16,816 for them.

CMS counts 118 Medicare patients who saw Dr. Castellanos in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Castellanos' median patient age at 70, with 53% women.

In 2024, Dr. Castellanos wrote 17 Medicare Part D claims for 15 patients. 94% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $10 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Castellanos for performance year 2024, reported as part of a group. Dr. Castellanos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Castellanos as offering telehealth.

Dmand AI links 24 papers to Dr. Castellanos, published from 2013 to 2024. 2018 was the busiest year, with 3. The most frequent topics are Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal and Cell Line, Tumor. Dr. Castellanos has published most often in Cancer Res. Dr. Castellanos' most frequent co-authors are Nipun B. Merchant, MD, Austin Richard Dosch, MD, PhD and Jeffrey M. Farma, MD.

CMS Open Payments shows 27 general payments to Dr. Castellanos from 6 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 93% of the total. Intera Oncology, Inc paid the most, $23,945.

Dmand AI lists 1 award for Dr. Castellanos.

Dr. Castellanos graduated from Vanderbilt University School Of Medicine in 2009. Dr. Castellanos is a member of ACS.

Dr. Castellanos is in network with 17 carriers, including Aetna, Elevance and Highmark. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.